MedPath

Invirsa, Inc.

Invirsa, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2016-01-01
Employees
1
Market Cap
-
Website
http://www.invirsa.com

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (75.0%)
Phase 1
1 (25.0%)

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Phase 2
Recruiting
Conditions
Non-center Involved Diabetic Macular Edema
Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Diabetic Retinopathy
Center-involved Diabetic Macular Edema
Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-04-24
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
24
Registration Number
NCT06599684
Locations
🇺🇸

MedTrials, Inc., Dallas, Texas, United States

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Vehicle
First Posted Date
2024-04-17
Last Posted Date
2025-07-02
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
109
Registration Number
NCT06370039
Locations
🇺🇸

iuvo BioScience, Rush, New York, United States

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Phase 2
Recruiting
Conditions
Acute Infectious Keratoconjunctivitis
Interventions
Drug: Vehicle
First Posted Date
2022-12-05
Last Posted Date
2024-05-16
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
102
Registration Number
NCT05636228
Locations
🇺🇸

Global Research Management, Glendale, California, United States

🇺🇸

Foothill Eye Institute, Pasadena, California, United States

🇺🇸

Shettle Eye Research, Largo, Florida, United States

and more 9 locations

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

Phase 1
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Vehicle
First Posted Date
2022-10-19
Last Posted Date
2024-04-10
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
84
Registration Number
NCT05586152
Locations
🇺🇸

iuvo BioScience, Rush, New York, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath